BOSTON SCIENTIFIC CORP
No SEC Form 4 filings for $BSX in the last 30 days.
Boston Scientific (BSX) fell about 12.5% to around $50.4 after management reiterated full-year guidance for “soft” organic growth and cited weaker demand in its WATCHMAN and urology franchises, according to the article. The company expects 2026 organic sales growth of 5.5%–7% and 6%–8% in Q2. Trading volume rose to ~49.5M shares.
U.S. stocks edged higher on May 27: the S&P 500 rose 0.03% to 7,521.29, the Nasdaq gained 0.07% to 26,674.73, and the Dow added 0.36% to 50,644.28, with chip and AI momentum supporting sentiment. Micron extended its rally. Constellation Energy fell nearly 4% after an analyst reset. Lululemon rose on a standstill agreement. AppLovin jumped 10% on a Morgan Stanley bullish view; Boston Scientific dropped after reiterating weaker-than-expected guidance.
The article is largely promotional and does not provide verifiable details about Boston Scientific’s trial results. It claims Boston Scientific’s pivotal trial enrolled patients with “over 93%” success, but no source, endpoint, or date is cited. It also promotes subscription offers and cites unrelated remarks about AI and robotics.
